Last updated: October 31, 2026
Onyx Therapeutics, Inc. sued Cipla Limited in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after Cipla submitted an abbreviated new drug application for a generic version of Kyprolis (carfilzomib) for injection. The dispute concerned patents covering carfilzomib and its pharmaceutical use. The case ended without a publicly reported merits judgment, leaving the commercial impact dependent on the parties’ settlement terms, Cipla’s FDA approval status, and the remaining Kyprolis patent estate.[1]
What drug and FDA application triggered the Onyx Therapeutics v. Cipla litigation?
The case involved Kyprolis, whose active ingredient is carfilzomib. Kyprolis is an intravenous proteasome inhibitor approved for the treatment of multiple myeloma.
Cipla’s ANDA sought approval for a generic carfilzomib product. Onyx filed the action after receiving notice of Cipla’s Paragraph IV certifications that the asserted patents were invalid, unenforceable, or would not be infringed by Cipla’s proposed product.
| Item |
Case detail |
| Brand drug |
Kyprolis |
| Active ingredient |
Carfilzomib |
| Dosage form |
Lyophilized powder for intravenous injection |
| NDA holder at filing |
Onyx Therapeutics, Inc. |
| ANDA applicant |
Cipla Limited |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:16-cv-00988 |
| Litigation type |
Hatch-Waxman patent infringement |
| Primary commercial issue |
Timing of generic carfilzomib entry |
Kyprolis was later commercialized within Amgen’s oncology portfolio following Amgen’s acquisition of Onyx. The acquisition did not eliminate the underlying patent rights or the litigation claims associated with Kyprolis.[2]
What patents did Onyx assert against Cipla?
The litigation involved patents directed to carfilzomib-related subject matter, including claims covering the active compound and pharmaceutical uses. Public case records identify U.S. Patent Nos. 8,822,438 and 9,266,951 among the relevant Kyprolis patents associated with the dispute.[1]
| Patent |
General subject matter |
Litigation relevance |
| U.S. Patent No. 8,822,438 |
Proteasome inhibitors and related compounds |
Composition and compound claims associated with carfilzomib |
| U.S. Patent No. 9,266,951 |
Carfilzomib-related treatment and pharmaceutical subject matter |
Method-of-use and product-related protection |
| U.S. Patent No. 7,232,828 |
Earlier proteasome-inhibitor patent family |
Important to the broader Kyprolis estate, although its relevance depends on the asserted claims and case pleadings |
Patent scope in a Hatch-Waxman case depends on the specific claims identified in the complaint and the defendant’s ANDA product. A patent may appear in the Orange Book without being asserted in every later case, and a patent asserted in litigation may cover only particular methods, formulations, or product characteristics.[3]
What were Cipla’s Paragraph IV defenses?
Cipla’s Paragraph IV certifications placed the validity and infringement of the asserted patents directly in dispute. The standard defenses in this type of case include:
- Non-infringement based on the composition, concentration, manufacturing process, or labeling of the proposed generic product.
- Invalidity for lack of novelty or obviousness.
- Lack of written description or enablement.
- Improper patent listing or lack of statutory relevance to the approved drug.
- Unenforceability based on inequitable conduct, if supported by the evidence.
The public record does not establish a merits ruling rejecting or upholding Cipla’s defenses. The case was resolved before a publicly reported final trial judgment. As a result, the docket does not provide a judicial determination of the ultimate validity or infringement strength of the asserted claims.[1]
When did the 30-month stay and generic entry restrictions apply?
A Paragraph IV notice generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii) when the NDA holder or patent owner files an infringement action within the statutory period. The stay prevents FDA approval of the ANDA during the statutory period unless the court enters a decision earlier or the stay is otherwise terminated.
The stay is distinct from patent expiration. A settlement can establish an agreed generic launch date that is earlier than a patent’s nominal expiration, subject to antitrust and regulatory review. The public docket does not disclose the complete commercial terms of the Onyx-Cipla resolution.[1]
How did the case end?
The action did not produce a publicly reported claim-construction decision, trial verdict, or final judgment invalidating the Kyprolis patents. The case was terminated through a negotiated resolution and dismissal.
| Litigation stage |
Publicly reported outcome |
| Complaint |
Filed in the District of Delaware in 2016 |
| ANDA dispute |
Based on Cipla’s proposed generic carfilzomib product |
| Markman ruling |
No publicly reported merits claim-construction decision identified |
| Trial |
No publicly reported trial verdict |
| Settlement |
Case resolved before a public merits judgment |
| Final disposition |
Dismissed pursuant to the parties’ resolution |
The settlement terms, including any permitted launch date, royalty structure, supply provisions, or restrictions on Cipla’s product, were not made public in the court docket. The absence of disclosed terms prevents a definitive conclusion about whether Onyx obtained a launch delay, an acceleration date, or other commercial concessions.
What is the Orange Book status of Kyprolis?
The Orange Book identifies patent and exclusivity information submitted by the NDA holder for approved drug products. Kyprolis’ Orange Book protection has included patents directed to carfilzomib, related compositions, and methods of treatment.[3]
Orange Book listing analysis must distinguish among:
- The original composition-of-matter patent.
- Later patents covering formulations or pharmaceutical compositions.
- Method-of-use patents associated with approved indications.
- Pediatric exclusivity or other statutory extensions.
- Patents that have expired, been delisted, or remain subject to litigation.
The existence of an Orange Book listing does not guarantee that the listed patent would survive an invalidity challenge. It does, however, create the statutory framework for Paragraph IV notice, infringement litigation, and the 30-month approval stay.
What formulation patents protect Kyprolis?
Kyprolis is supplied as a sterile lyophilized powder that is reconstituted before intravenous administration. Formulation and manufacturing protection can cover:
- Stabilized carfilzomib compositions.
- Lyophilized formulations.
- Excipient selection and concentration.
- Reconstitution characteristics.
- Storage stability.
- Container closure and handling requirements.
- Manufacturing steps that produce the finished drug.
Formulation claims can create a separate barrier from the active-ingredient patent. A generic applicant may avoid a formulation patent by using a different excipient system or manufacturing process, but that strategy may create regulatory, equivalence, stability, or commercial-development risks.
The public litigation record does not establish that Cipla adopted a formulation materially different from Kyprolis or that a court adjudicated those technical differences. The strongest commercial risk generally arises when the generic must use a similar formulation to achieve the required stability and injectable performance.
What method-of-use patents affect carfilzomib generic entry?
Method-of-use patents may cover treatment of multiple myeloma with carfilzomib in specified patient populations, dosing regimens, combinations, or treatment lines. These patents can create regulatory complexity because an ANDA applicant may use a section viii statement to omit patented indications from its labeling.
A section viii carve-out is viable only if the proposed labeling does not encourage infringement of the patented method. The analysis depends on:
- The exact approved indication.
- The scope of the patent claims.
- The generic label.
- Physician prescribing patterns.
- Product literature and promotional conduct.
- Whether the patented use is inseparable from the unpatented indication.
For Kyprolis, use patents may affect the commercial value of a generic even if the ANDA applicant obtains approval for a narrower label. Oncologists may still prescribe the generic for multiple indications, creating potential off-label-use and inducement disputes.
How strong was the Onyx patent estate?
The estate had meaningful strength because it combined multiple patent categories rather than relying solely on one composition patent.
| Estate component |
Strategic value |
Main vulnerability |
| Active compound claims |
Can block direct substitution with the same molecule |
Expiration and invalidity risk |
| Pharmaceutical composition claims |
Can restrict equivalent injectable products |
Design-around potential |
| Method-of-use claims |
Can preserve indication-specific exclusivity |
Label carve-outs |
| Manufacturing claims |
Can increase development and process risk |
Difficult infringement proof if process is performed abroad |
| Orange Book listings |
Trigger Paragraph IV procedures and potential stays |
Listing, claim-scope, and delisting challenges |
The estate’s practical strength was higher than the strength of any single patent because a generic applicant faced cumulative regulatory and litigation issues. Its practical weakness was that the case ended without a judicial ruling, leaving the enforceability and validity of the asserted claims unresolved.
Which companies challenged or competed with Kyprolis?
The key competitor in this case was Cipla. Other potential competitive pressure came from:
- Generic injectable oncology manufacturers.
- Companies developing alternative proteasome inhibitors.
- Suppliers of bortezomib, ixazomib, and other multiple myeloma therapies.
- Branded therapies used in combination regimens.
- Biosimilar developers targeting other products in the multiple myeloma market.
Biosimilar risk was not the principal issue in this case. Carfilzomib is a chemically synthesized small molecule rather than a biologic, so the relevant pathway is an ANDA rather than a biosimilar application under the Biologics Price Competition and Innovation Act.
What revenue exposure did the litigation create?
Kyprolis was a material oncology product for Onyx and later Amgen. Generic entry would affect revenue through:
- Price erosion from generic substitution.
- Reduced volume in multiple myeloma treatment regimens.
- Payer-mandated substitution.
- Lower net sales after launch of an authorized generic or third-party generic.
- Loss of bargaining leverage in hospital and specialty-pharmacy channels.
The case-specific revenue exposure cannot be calculated from the docket because the settlement date and any agreed generic launch date were not publicly disclosed. The commercial impact therefore depended on whether Cipla received an early-entry right and whether other ANDA applicants could enter independently.
What generic launch scenarios followed the settlement?
Three commercial scenarios were possible:
- Cipla remained blocked until the relevant patent or exclusivity period ended.
- Cipla received a negotiated early-entry date, potentially subject to a confidential settlement.
- Cipla obtained approval but faced additional product, manufacturing, or commercial limitations.
A settlement does not itself establish that the patents were weak. Brand companies may settle to limit litigation cost, preserve a predictable launch date, secure supply or licensing terms, or avoid an adverse validity ruling. Generic applicants may settle to obtain commercial certainty and avoid the risk of delayed approval.
Key Takeaways
- Onyx sued Cipla in Delaware over an ANDA for generic Kyprolis, or carfilzomib for injection.
- The dispute involved carfilzomib-related patents, including U.S. Patent Nos. 8,822,438 and 9,266,951.
- Cipla’s Paragraph IV certifications placed patent validity and infringement at issue.
- The case ended without a publicly reported trial verdict or merits judgment.
- The settlement terms and any agreed generic launch date were not publicly disclosed.
- The broader Kyprolis estate included composition, formulation, method-of-use, and manufacturing protections.
- Biosimilar law was not the relevant framework because carfilzomib is a small-molecule drug.
- The litigation reduced immediate generic-entry certainty but did not produce a precedential ruling confirming the patents’ validity or enforceability.
FAQs About Onyx Therapeutics v. Cipla
Was Onyx Therapeutics v. Cipla a Hatch-Waxman case?
Yes. The lawsuit arose from Cipla’s ANDA and Paragraph IV certifications for a generic carfilzomib product.
Did Cipla win the Kyprolis patent case?
No public merits judgment awarded victory to either side. The case was resolved and dismissed before a publicly reported final trial decision.
Is Kyprolis a biologic subject to biosimilar competition?
No. Kyprolis contains carfilzomib, a chemically synthesized small-molecule active ingredient. Generic competition proceeds through the ANDA pathway.
Did the settlement disclose Cipla’s generic launch date?
The public docket did not disclose the complete settlement terms or a definitive Cipla launch date.
Which patent categories matter most for generic carfilzomib?
Composition-of-matter, pharmaceutical formulation, method-of-use, and manufacturing patents all can affect generic entry. The commercial importance depends on claim scope, patent expiration, FDA labeling, and the generic product’s design.
References
-
U.S. District Court for the District of Delaware. (2016). Onyx Therapeutics, Inc. v. Cipla Limited, No. 1:16-cv-00988. PACER docket records.
-
Amgen Inc. (2013). Amgen completes acquisition of Onyx Pharmaceuticals. Amgen corporate disclosures.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,822,438, Proteasome inhibitors and methods of use thereof. Google Patents.
-
U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,266,951. Google Patents.
-
21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.
